Navigator Medicines, Inc. raised $100M in a Series A funding round co-led by RA Capital Management and Forbion to advance their bispecific antibody NAV-240 for autoimmune diseases.
Navigator Medicines, Inc. raised $100M in a Series A funding round co-led by RA Capital Management and Forbion to advance their bispecific antibody NAV-240 for autoimmune diseases.
08/27/24, 11:04 AM
Location
scotch plainsMoney raised
$100 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Forbion, Ra Capital Management
Navigator Medicines, Inc. has successfully closed a $100 million Series A financing to further develop NAV-240, a bispecific antibody targeting OX40L and TNFα. The funding will accelerate the clinical development of this innovative therapeutic and enhance their broader pipeline of immune regulation biologics.
Company Info
Location
scotch plains, new jersey, united states
Additional Info
Navigator Medicines is a biotech company leading the advancement of biologics for targeted immune regulation & restoration. Founded in 2024 as a subsidiary of Sera Medicines, the Company is committed to developing new therapies for patients living with complex, heterogeneous autoimmune diseases. NAV-240, their clinical-stage bispecific antibody, targets OX40L and TNFα to address critical inflammatory diseases. The company is focused on innovation that enhances patient care.